Pyxis Oncology, Inc. (NASDAQ:PYXS) Short Interest Update

Pyxis Oncology, Inc. (NASDAQ:PYXS) was the target of a significant growth in short interest during the month of October. As of October 31st, there was short interest totalling 5,860,000 shares, a growth of 19.3% from the October 15th total of 4,910,000 shares. Based on an average trading volume of 504,200 shares, the days-to-cover ratio is presently 11.6 days. Approximately 13.3% of the company’s shares are short sold.

Pyxis Oncology Stock Performance

Pyxis Oncology stock traded down $0.09 during mid-day trading on Friday, reaching $4.19. The stock had a trading volume of 793,622 shares, compared to its average volume of 750,478. The firm has a market capitalization of $249.18 million, a PE ratio of -4.07 and a beta of 1.27. Pyxis Oncology has a fifty-two week low of $1.35 and a fifty-two week high of $6.85. The stock’s 50-day simple moving average is $3.69 and its 200-day simple moving average is $3.65.

Pyxis Oncology (NASDAQ:PYXS) last posted its quarterly earnings results on Wednesday, August 14th. The company reported ($0.29) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.33) by $0.04. On average, research analysts forecast that Pyxis Oncology will post -1.03 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of analysts have weighed in on the company. Stephens started coverage on Pyxis Oncology in a report on Friday, November 8th. They set an “overweight” rating and a $13.00 price target for the company. HC Wainwright reiterated a “buy” rating and issued a $7.00 target price on shares of Pyxis Oncology in a report on Friday, August 16th. Royal Bank of Canada reissued an “outperform” rating and issued a $7.00 price target on shares of Pyxis Oncology in a research note on Thursday, September 19th. Finally, Stifel Nicolaus started coverage on shares of Pyxis Oncology in a research report on Thursday, August 8th. They set a “buy” rating and a $10.00 price objective for the company. Eight equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, Pyxis Oncology presently has an average rating of “Buy” and a consensus price target of $9.57.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the business. Fullcircle Wealth LLC purchased a new stake in shares of Pyxis Oncology in the second quarter worth approximately $40,000. Intech Investment Management LLC purchased a new position in shares of Pyxis Oncology during the third quarter valued at approximately $55,000. SG Americas Securities LLC bought a new stake in Pyxis Oncology during the third quarter worth $58,000. The Manufacturers Life Insurance Company purchased a new stake in Pyxis Oncology in the 2nd quarter valued at $65,000. Finally, MetLife Investment Management LLC raised its position in Pyxis Oncology by 41.1% in the 3rd quarter. MetLife Investment Management LLC now owns 18,818 shares of the company’s stock valued at $69,000 after buying an additional 5,484 shares during the last quarter. Institutional investors and hedge funds own 39.09% of the company’s stock.

Pyxis Oncology Company Profile

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.